Kawasaki Takahiro, Takeda Yoshito, Kumanogoh Atsushi
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Department of Immunopathology, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan.
Inflamm Regen. 2024 Sep 18;44(1):38. doi: 10.1186/s41232-024-00351-4.
Inflammatory respiratory diseases, such as interstitial lung disease (ILD), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), and respiratory infections, remain significant global health concerns owing to their chronic and severe nature. Emerging as a valuable resource, blood extracellular vesicles (EVs) offer insights into disease pathophysiology and biomarker discovery in these conditions.
This review explores the advancements in blood EV proteomics for inflammatory respiratory diseases, highlighting their potential as non-invasive diagnostic and prognostic tools. Blood EVs offer advantages over traditional serum or plasma samples. Proteomic analyses of blood EVs have revealed numerous biomarkers that can be used to stratify patients, predict disease progression, and identify candidate therapeutic targets. Blood EV proteomics has identified proteins associated with progressive fibrosis in ILD, offering new avenues of treatment. In BA, eosinophil-derived EVs harbor biomarkers crucial for managing eosinophilic inflammation. Research on COPD has also identified proteins that correlate with lung function. Moreover, EVs play a critical role in respiratory infections such as COVID-19, and disease-associated proteins are encapsulated. Thus, proteomic studies have identified key molecules involved in disease severity and immune responses, underscoring their role in monitoring and guiding therapy.
This review highlights the potential of blood EV proteomics as a non-invasive diagnostic and prognostic tool for inflammatory respiratory diseases, providing a promising avenue for improved patient management and therapeutic development.
炎症性呼吸系统疾病，如间质性肺疾病（ILD）、支气管哮喘（BA）、慢性阻塞性肺疾病（COPD）和呼吸道感染，因其慢性和严重性，仍然是全球重大的健康问题。血液细胞外囊泡（EVs）作为一种宝贵的资源，为这些疾病的病理生理学和生物标志物发现提供了见解。
本综述探讨了血液EV蛋白质组学在炎症性呼吸系统疾病方面的进展，强调了其作为非侵入性诊断和预后工具的潜力。血液EVs比传统的血清或血浆样本具有优势。对血液EVs的蛋白质组学分析揭示了许多可用于对患者进行分层、预测疾病进展和识别候选治疗靶点的生物标志物。血液EV蛋白质组学已鉴定出与ILD中进行性纤维化相关的蛋白质，为治疗提供了新途径。在BA中，嗜酸性粒细胞衍生的EVs含有对管理嗜酸性粒细胞炎症至关重要的生物标志物。对COPD的研究也确定了与肺功能相关的蛋白质。此外，EVs在COVID-19等呼吸道感染中起关键作用，且疾病相关蛋白被包裹其中。因此，蛋白质组学研究已确定了参与疾病严重程度和免疫反应的关键分子，强调了它们在监测和指导治疗中的作用。
本综述强调了血液EV蛋白质组学作为炎症性呼吸系统疾病非侵入性诊断和预后工具的潜力，为改善患者管理和治疗发展提供了一条有前景的途径。
